肿瘤坏死因子抑制剂治疗与长期非黑色素瘤皮肤癌及黑色素瘤风险增加相关:一项回顾性队列研究
该回顾性队列研究纳入1996至2020年56,209例慢性炎症性疾病成人患者,其中13,377例有TNF-α抑制剂暴露。多变量Cox比例风险分析显示,TNF-I暴露与任何皮肤恶性肿瘤、黑色素瘤、鳞状细胞癌和基底细胞癌风险增加显著相关,但未发现非黑色素瘤皮肤癌组织病理学严重程度或黑色素瘤临床分期的显著差异。
要点
- TNF-I暴露与皮肤恶性肿瘤风险增加显著相关。
- 风险增加涉及黑色素瘤、鳞状细胞癌和基底细胞癌。
- 未观察到肿瘤严重程度或分期的显著差异。
核心结论
- TNF-I治疗与炎症性疾病患者非黑色素瘤皮肤癌和黑色素瘤诊断风险增加相关,但与严重程度无关。
研究设计与样本
- 回顾性队列研究,纳入1996至2020年慢性炎症性疾病成人患者56,209例,其中13,377例有TNF-I暴露。
主要发现
- TNF-I暴露与任何皮肤恶性肿瘤风险增加显著相关。
- TNF-I暴露与黑色素瘤风险增加显著相关。
- TNF-I暴露与鳞状细胞癌风险增加显著相关。
- TNF-I暴露与基底细胞癌风险增加显著相关。
- TNF-I暴露与未暴露患者间非黑色素瘤皮肤癌组织病理学严重程度或黑色素瘤临床分期无显著差异。
临床怎么用
- 处方TNF-I时应意识到皮肤癌风险增加,可能影响皮肤癌筛查模式。
局限性
- 回顾性设计。
- 患者层面风险因素记录存在变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TNF-α inhibitors (TNF-I) are widely used to treat chronic inflammatory diseases, although there may be an associated risk of nonmelanoma skin cancer (NMSC) and melanoma. OBJECTIVE: To evaluate if TNF-I exposure is associated with an increased risk or severity of NMSC or melanoma. METHODS: A retrospective cohort study of adults with chronic inflammatory disease from 1996 to 2020. Primary outcome was basal cell carcinoma, squamous cell carcinoma, or melanoma diagnosis. Skin cancer diagnosis identified via International Classification of Diseases code and TNF-I exposure were manually reviewed for accuracy. Differential malignancy risk was analyzed by multivariable Cox proportional hazards to determine adjusted hazard ratios with disease severity stratification. RESULTS: Of 56,209 patients with chronic inflammatory conditions, 13,377 had TNF-I exposure. TNF-I exposure was significantly associated with increased risk of any cutaneous malignancy, melanoma, squamous cell carcinoma, and basal cell carcinoma. No significant differences in NMSC histopathological severity or melanoma clinical stage were found between TNF-I exposed and unexposed patients. LIMITATIONS: Retrospective design, variability in patient-level risk factor documentation. CONCLUSION: TNF-I therapy in patients with inflammatory disease is associated with increased risk of NMSC and melanoma diagnosis but not severity. Prescribers of TNF-I should be aware of this increased risk, which may impact skin cancer screening patterns.
引用
- Driscoll CB, Schwab G, Quan VL, et al. Tumor necrosis alpha inhibitor therapy is associated with increased long-term risk of nonmelanoma skin cancer and melanoma: A retrospective cohort study. J Am Acad Dermatol. 2026. PMID: 41707711. doi:10.1016/j.jaad.2026.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。